Diabetes-induced upregulation of renal Cd14 was also no longer present in the mice treated with empagliflozin (mono- and co-treatment with metformin), but not metformin, suggesting that the aforementioned benefits with SGLT2 inhibition may have been mediated through reduced inflammation. The gene discussed is CD14; the disease is diabetes mellitus.